Drug Trial Radar · NCT05688215
Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma
Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
141
Planned (sponsor's estimate)
Start
Mar 7, 2023
Primary completion
Dec 31, 2027
Study completion Dec 31, 2028
Sponsor
- Lead sponsor
- Jonsson Comprehensive Cancer CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Arcus Biosciences, Inc.; Congressionally Directed Medical Research Programs
- First posted
- Jan 18, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase I/II study tests how well zimberelimab and quemliclustat work in combination with chemotherapy (mFOLFIRINOX) in treating patients pancreatic adenocarcinoma that may or may not be able to be removed by surgery (borderline resectable) or that has spread to nearby tissue or lymph nodes (locally advanced). Immunotherapy with monoclonal antibodies, such as zimberelimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Quemliclustat acts as a blocker for adenosine. Adenosine is a chemical produced in the body that can lead to a decrease in the immune system's response towards cancer. Quemliclustat has the potential to decrease the amount of adenosine, allowing the immune system to recognize and act against the cancer. Chemotherapy drugs, such as oxaliplatin, irinotecan, leucovorin, and fluorouracil, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy in combination with zimberelimab and quemliclustat may kill more cancer cells than chemotherapy alone.
Conditions
- Borderline Resectable Pancreatic Adenocarcinoma
- Locally Advanced Pancreatic Ductal Adenocarcinoma
Interventions
Biospecimen CollectionProcedure
Undergo collection of blood and tissue samples
Computed TomographyProcedure
Undergo a CT scan
Core BiopsyProcedure
Undergo core biopsy
FluorouracilDrug
Given IV
IrinotecanDrug
Given IV
LeucovorinDrug
Given IV
Leucovorin CalciumDrug
Given IV
OxaliplatinDrug
Given IV
QuemliclustatDrug
Given intravenously (IV)
ZimberelimabDrug
Given IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of adverse events (BPRC Cohort)Time frame: From baseline measurement to 90 days after the last dose of study treatment.
- Resection rate (BPRC Cohort)Time frame: Up to 2 years
- Progression free survival (PFS) (LAPC Cohort)Time frame: Up to 2 years
- Number of participants who develop clinically relevant pancreatic fistula (BPRC Cohort)Time frame: Up to 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Yonemoto,Lisa
Los Angeles, California · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.